GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects

Documenti analoghi

• GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without ketamine-like Side Effects
  di: Burgdorf, Jeffrey, et al.
  Pubblicazione: (2013)
• GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists
  di: Moskal, Joseph R, et al.
  Pubblicazione: (2013)
• The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant
  di: Moskal, Joseph R., et al.
  Pubblicazione: (2017)
• The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/Glycine(B)-Site Inhibition
  di: Zanos, Panos, et al.
  Pubblicazione: (2015)
• The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus
  di: Burgdorf, Jeffrey, et al.
  Pubblicazione: (2015)